in the News
gets FDA approval
Imaging Corporation of Denver, Colorado, has received Food and Drug
Administration approval for its digital mammography system, which
was initially developed in collaboration with Lawrence Livermore
scientists and engineers under a Cooperative Research and Development
Agreement between 1993 and 1996.
FDA approval of SensoScan,
the Fischer Imaging system, means that the federal agency has found
the digital system to be safe and effective for use in the same
clinical applications as traditional mammography. FDA approval also
means that SensoScan becomes available for regular clinical use
to treat patients. Previously, it could only be used in a research
mammography technology uses film to record the x-ray image of breast
tissue. SensoScan records the image electronically. Thus, tissue
images can be acquired at one location and rapidly transmitted to
another site for interpretation.
yet, with digital mammography, computers can now be used to help
diagnose and evaluate the high-fidelity digital tissue images. According
to Livermore mechanical engineer Clint Logan, who heads the collaboration
with Fischer, image variables such as contrast and brightness can
be adjusted on computer display, not fixed by film chemistry and
exposure. Thus, the possibility of human error or misinterpretation
Laboratorys ability to assist in the development of digital
mammography grew out of work performed for ballistic missile defense,
specifically the X-Ray Laser Program. When the U.S. ended that program,
the Livermore team applied the materials analysis and characterization
tools and expertise developed for the x-ray laser to other technologies,
including digital mammography.
Contact: Stephen Wampler (925) 423-3107 (email@example.com).
cosponsors tribes energy conference
In late August, the Laboratory
cosponsored a two-day conference on energy solutions with the Council
of Energy Resource Tribes (CERT). The conference attracted 350 participants
representing nearly 50 American and Canadian Indian tribes, private
industry, the University of California, and the Department of Energy.
This is the 20th year that
CERT has held the conference and the first time it has asked a national
laboratory to be a cosponsor, according to Livermores Karen
Kiernan, who coordinated Livermores involvement in the conference.
is a coalition of 44 American Indian tribes and 4 Canadian affiliate
members that own a substantial share of North Americas energy
conference, held in San Jose, California, included workshops on
Indian energy solutions such as conservation, natural resource strategies,
and tribal policies.
tribes are working to have a much stronger technical and managerial
role in developing energy resources on tribal lands than in the
past, when they principally received only royalties.
conference also included the American Spirit Awards dinner, a fund-raiser
for CERTs scholarship fund. At this dinner, Steve Grey, representative
for the DOELivermore American Indian Program field office,
presented two scholarships to essay winners on behalf of the Laboratory.
Contact: Karen Kiernan (925) 423-9051 (firstname.lastname@example.org).
to partner on dialysis equipment
Following lengthy negotiations
led by Laboratory representatives, the first joint commercial venture
between a former Russian weapons manufacturer and a U.S. firm has
been formally signed.
Plant in Russia and Fresenius Medical Care in the U.S. will establish
a commercial medical equipment manufacturing facility in Sarov,
Russia. The new company, called FRESAR, will produce high-quality,
low-cost kidney dialysis equipment.
The project is part
of the National Nuclear Security Administrations (NNSAs)
Nuclear Cities Initiative (NCI), which seeks to reduce the risk
of nuclear proliferation by helping create civilian jobs for displaced
weapons workers in the former Soviet Union. The project also receives
funding from NNSAs Initiatives for Proliferation Prevention
FRESAR will build
assembly lines for disposable medical products used in Fresenius
kidney dialysis equipment. The lines are expected to be fully operational
by the end of 2003, with products to be marketed by Fresenius in
Russia and other European countries.
The venture was spearheaded
by Ann Heywood, leader of the Laboratorys Russian medical
technologies work in support of NCI, and Jim Trebes of the Physics
and Advanced Technology Directorates Medical Technology program.
The project is managed by the Nonproliferation, Arms Control, and
International Security Directorate.
Contact: Ann Heywood (925) 422-2773 (email@example.com).